Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma

Investigational New Drugs

Volumn 23, Issue 6, 2005, Pages 577-581

  Shaheen, Philip E ^a   Stadler, Walter ^b   Elson, Paul ^a   Knox, Jennifer ^c   Winquist, Eric ^d   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

GD0039; Phase II trial; Renal cell carcinoma

Indexed keywords

1,2,8 TRIHYDROINDOLIZIDINIUM CHLORIDE; AMYLASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; GD 0039; INDOLIZIDINE DERIVATIVE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CARCINOMA; MALE; MENTAL CONCENTRATION; METASTASIS; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SLURRED SPEECH; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MANNOSIDASES; PHYTOHEMAGGLUTININS; SWAINSONINE;

EID: 31544482694     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-0793-z     Document Type: Article

References (22)

1. American Cancer Society. Cited July 28, 2004; available from: www.cancer.org/downloads/PRO/Cancer%20Statistics%202004. ppt
2. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 166(5): 1611-1623, 2001
3. Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer 80(7): 1198-1220, 1997
4. Dennis JW, Laferte S: Tumor cell surface carbohydrate and the metastatic phenotype. Cancer Metastasis Rev 5(3): 185-204, 1987
5. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS: Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236(4801): 582-585, 1987
6. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW: Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 51(2): 718-723, 1991
7. Olden K, Breton P, Grzegorzewski K, Yasuda Y, Gause BL, Oredipe OA, Newton SA, White SL: The potential importance of swainsonine in therapy for cancers and immunology. Pharmacol Ther 50(3): 285-290, 1991
8. Galustian C, Foulds S, Dye JF, Guillou PJ: Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity. Immunopharmacology 27(2): 195-172, 1994
9. Korczak B, Goss P, Fernandez B, Baker M, Dennis JW: Branching N-linked oligosaccharides in breast cancer. Adv Exp Med Biol 353: 95-104, 1994
10. Goss PE, Baker MA, Carver JP, Dennis JW: Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin Cancer Res 1(9): 935-944, 1995
11. Mohla S, White S, Grzegorzewski K, Nielson D, Dunston G, Dickson L, Cha JK, Asseffa A, Olden K: Inhibition of growth of subcutaneous xenografts and metastasis of human breast carcinoma by swainsonine: modulation of tumor cell HLA class I antigens and host immune effector mechanisms.
12. Goss PE, Reid CL, Bailey D, Dennis JW: Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin Cancer Res 3(7): 1077-1086, 1997
13. Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW: A phase I study of swainsonine in patients with advanced malignancies. Cancer Res 54(6): 1450-1457, 1994
14. Bjarnason GA, Walde D, Whelan P, Chin J, Batist G: GD0039 in solid tumors. American Society of Clinical Oncology Annual Meeting 2002, abstract # 2494
15. Suzuki O, Nozawa Y, Kawaguchi T, Abe M: Alpha-2, 6-sialylation of L-PHA reactive oligosaccharides and expression of N-acetylglucosaminyltransferase V in human diffuse large B cell lymphoma. Oncol Rep 10(6): 1759-1764, 2003
16. Baptista JA, Goss P, Nghiem M, Krepinsky JJ, Baker M, Dennis JW: Measuring swainsonine in serum of cancer patients: Phase I clinical trial. Clin Chem 40(3): 426-430, 1994
17. World Health Organization Staff. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO offset publication No 40, 1979
18. Bukowski RM, Novick AC: Clinical practice guidelines: Renal cell carcinoma. Cleve Clin J Med 64 Suppl 1:SI1-44; quiz SI45-7, 1997
19. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL: Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9(5):1648-1655, 2003.
20. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell carcinoma. J Clin Oncol 22(15): 3003-3015, 2004
21. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21(1): 99-101, 2003
22. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti- vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5): 427-434, 2003